BioMarin Pharmaceuticals
BMRN
321 hedge funds and large institutions have $8.94B invested in BioMarin Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 128 increasing their positions, 103 reducing their positions, and 36 closing their positions.
40% more call options, than puts
Call options by funds: $140M | Put options by funds: $100M
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
25% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 36
24% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 103
3% more funds holding
Funds holding: 313 → 321 (+8)
14% less capital invested
Capital invested by funds: $10.4B → $8.94B (-$1.45B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$132M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$116M |
| 3 |
Millennium Management
New York
|
+$82M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$67.5M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$35.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$291M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$177M |
| 3 |
Jennison Associates
New York
|
-$161M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$76.4M |
| 5 |
HCM
Holland Capital Management
Chicago,
Illinois
|
-$53.2M |
BMRN Hedge Fund Activity: Q2 2014 in Review
321 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2014, worth a combined $8.94B — down 14% from $10.4B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BMRN positions and 36 closed out — a net gain of 9 holders — while 128 added to existing stakes and 103 trimmed.
The largest buyer was Sands Capital Management, adding an estimated $132M. The largest seller was Winslow Capital Management, cutting an estimated $291M.
- 321 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2014, up from 313 in Q1 2014.
- Funds reported $8.94B of BioMarin Pharmaceuticals stock for Q2 2014, down 14% quarter-over-quarter.
- 45 funds opened new BioMarin Pharmaceuticals positions in Q2 2014 and 36 closed out, a net change of +9 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2014 was Sands Capital Management, an estimated $132M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2014 was Winslow Capital Management, an estimated $291M sold.
Based on aggregated 13F filings for Q2 2014.